Expanding Bone Marrow-Derived Immune Regulatory Cells and Immune Regulatory B cells by Activating GPCR19 Pathway In vivo or In vitro

The present invention provides a screening method of therapeutic agents for diseases associated GPCR19-. In another aspect, the present invention provides the efficacy analysis of the GPCR19 agonist. In another aspect, the present invention provides the MDSC (Myeloid suppressor cell-derived) having the in vivo biological activity regulatory substance and GPCR19 agonist is formed agonist treatment Gr-1 The invention also provides the in vivo physiological activity regulatory substance and GPCR19 agonists are processed to form, or is formed by a H-MDSC treatment (Regulatory B cell) immune regulation B cells with anti-inflammatory activity has a B220 In another aspect, the present invention provides an anti-inflammatory pharmaceutical composition comprising a H-MDSC or B In another aspect, the present invention provides an anticancer pharmaceutical composition comprising a In another aspect, the present invention provides an anti-inflammatory pharmaceutical composition comprising an agonist GPCR19 composition for the purpose of amplifying in vivo a MDSC H-B or According to the present invention, lipopolysaccharide (LPS) because of the administration in the inflammation-induced mice with sodium tauro deoxycholate (HY-2191) increased the number of H-MDSC cells by administration and increasing H-MDSC of the It shows a significant sepsis treatment. Increase in the number of lipopolysaccharide (LPS) immunomodulatory B cells (48h B According to the present invention, lipopolysaccharide (LPS) increased in mice Inflammation is induced by administration by the administration of Cells show a significant sepsis treatment.